S A Mousa

Summary

Affiliation: Albany College of Pharmacy
Country: USA

Publications

  1. ncbi Anti-thrombotics in thrombosis and cancer
    Shaker A Mousa
    Pharmaceutical Research Institute PRI, Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208 3492, USA
    Future Oncol 1:395-403. 2005
  2. ncbi Role of current and emerging antithrombotics in thrombosis and cancer
    Shaker A Mousa
    Pharmaceutical Research Institute, Albany College of Pharmacy, Albany, New York 12208, USA
    Drugs Today (Barc) 42:331-50. 2006
  3. ncbi Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model
    S A Mousa
    The Pharmaceutical Research Institute, Albany College of Pharmacy, Albany, NY, USA
    Int Angiol 25:407-13. 2006
  4. ncbi Cell adhesion molecules: potential therapeutic & diagnostic implications
    Shaker A Mousa
    The Pharmaceutical Research Institute, Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY, USA
    Mol Biotechnol 38:33-40. 2008
  5. pmc Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers
    Dhruba J Bharali
    Pharmaceutical Research Institute at Albany College of Pharmacy, Rensselaer, NY, USA
    Int J Nanomedicine 4:1-7. 2009
  6. pmc Preferred drug lists: potential impact on healthcare economics
    Kimberly Ovsag
    Pharmaceutical Research Institute at Albany College of Pharmacy, Albany, New York 12208, USA
    Vasc Health Risk Manag 4:403-13. 2008
  7. ncbi Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia
    Shaker A Mousa
    Pharmaceutical Research Institute, Albany College of Pharmacy, Albany, New York 12208, USA
    Am J Hematol 82:276-82. 2007
  8. ncbi Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist
    Shaker A Mousa
    Pharmaceutical Research Institute, Albany College of Pharmacy, Albany, NY 12208, USA
    Anticancer Res 25:197-206. 2005
  9. ncbi Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans
    Shaker A Mousa
    Pharmaceutical Research Institute and Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208 3492, USA
    Blood Coagul Fibrinolysis 16:165-71. 2005
  10. ncbi Effect of low molecular weight heparin and different heparin molecular weight fractions on the activity of the matrix-degrading enzyme aggrecanase: structure-function relationship
    Shaker A Mousa
    Pharmaceutical Research Institute and Albany College of Pharmacy, Albany, New York 12208, USA
    J Cell Biochem 95:95-8. 2005

Detail Information

Publications90

  1. ncbi Anti-thrombotics in thrombosis and cancer
    Shaker A Mousa
    Pharmaceutical Research Institute PRI, Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208 3492, USA
    Future Oncol 1:395-403. 2005
    ..Additionally, antiplatelet drugs may have an impact on tumor metastasis, and the combination of antiplatelets and anticoagulants at adjusted doses may provide greater benefits to cancer patients...
  2. ncbi Role of current and emerging antithrombotics in thrombosis and cancer
    Shaker A Mousa
    Pharmaceutical Research Institute, Albany College of Pharmacy, Albany, New York 12208, USA
    Drugs Today (Barc) 42:331-50. 2006
    ..Furthermore, a number of orally active direct antithrombin and anti-factor Xa are in advanced clinical development for various thromboembolic disorders...
  3. ncbi Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model
    S A Mousa
    The Pharmaceutical Research Institute, Albany College of Pharmacy, Albany, NY, USA
    Int Angiol 25:407-13. 2006
    ..Our laboratory has recently demonstrated the pro-angiogenesis effects of thyroid hormone in the chick chorioallantoic membrane model...
  4. ncbi Cell adhesion molecules: potential therapeutic & diagnostic implications
    Shaker A Mousa
    The Pharmaceutical Research Institute, Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY, USA
    Mol Biotechnol 38:33-40. 2008
    ....
  5. pmc Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers
    Dhruba J Bharali
    Pharmaceutical Research Institute at Albany College of Pharmacy, Rensselaer, NY, USA
    Int J Nanomedicine 4:1-7. 2009
    ..This review provides a brief description of nanoparticle (liposome, quantum dot, and dendrimer)-mediated cancer therapy in the last decade with an emphasis on the development and use of dendrimers in cancer therapeutics...
  6. pmc Preferred drug lists: potential impact on healthcare economics
    Kimberly Ovsag
    Pharmaceutical Research Institute at Albany College of Pharmacy, Albany, New York 12208, USA
    Vasc Health Risk Manag 4:403-13. 2008
    ..To analyze the implementation of Medicaid preferred drug lists (PDLs) in a number of states and determine its impact on quality of care and cost relative to other segments of healthcare...
  7. ncbi Platelet GPIIb/IIIa antagonist, XV459, in heparin-induced thrombocytopenia
    Shaker A Mousa
    Pharmaceutical Research Institute, Albany College of Pharmacy, Albany, New York 12208, USA
    Am J Hematol 82:276-82. 2007
    ..The platelet GPIIb/IIIa receptor antagonist (XV459) might be of potential benefit in the management of thrombotic thrombocytopenia produced by heparin and/or related glycosaminoglycans...
  8. ncbi Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist
    Shaker A Mousa
    Pharmaceutical Research Institute, Albany College of Pharmacy, Albany, NY 12208, USA
    Anticancer Res 25:197-206. 2005
    ..Angiogenesis is a complex process involving endothelial cell migration, proliferation, invasion, and tube formation. Inhibition of these processes might have implications in various angiogenesis-mediated disorders...
  9. ncbi Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans
    Shaker A Mousa
    Pharmaceutical Research Institute and Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208 3492, USA
    Blood Coagul Fibrinolysis 16:165-71. 2005
    ..These data indicate (not studied) that roxifiban, at a targeted clinical dosing regimen, failed to achieve sufficient exposure to modulate platelet-mediated clot retraction...
  10. ncbi Effect of low molecular weight heparin and different heparin molecular weight fractions on the activity of the matrix-degrading enzyme aggrecanase: structure-function relationship
    Shaker A Mousa
    Pharmaceutical Research Institute and Albany College of Pharmacy, Albany, New York 12208, USA
    J Cell Biochem 95:95-8. 2005
    ..The aggrecanase inhibitory effect of LMWH might contribute to blocking inflammation and tumor invasion by inhibiting aggrecanase activity and maintaining an intact extracellular matrix barrier...
  11. ncbi Human alphavbeta3 integrin potency and specificity of TA138 and its DOTA conjugated form (89)Y-TA138
    Shaker A Mousa
    Albany College of Pharmacy, Albany, New York 12208 3492, USA
    J Cardiovasc Pharmacol 45:109-13. 2005
    ..Both 89Y-TA138 and TA138 demonstrated comparable alphavbeta3 affinity and specificity as compared with other closely related human integrins such as alphavbeta5, alphaIIbbeta3, or alpha5beta1...
  12. ncbi Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy
    Shaker A Mousa
    Pharmaceutical Research Institute, Albany College of Pharmacy, Albany, NY 12208, USA
    Oncol Rep 12:683-8. 2004
    ..Thus, the LMWH tinzaparin, in addition to its anticoagulant effects, may offer important benefits in treatment of cancer and other disorders supported by pathologic angiogenesis...
  13. ncbi Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor
    Shaker A Mousa
    Albany College of Pharmacy and Pharmaceutical Research Institutes, New York, USA
    Thromb Haemost 92:627-33. 2004
    ..These results suggest that the inhibitory effect of the LMWH tinzaparin on endothelial tube formation is associated with stimulation of the release of TFPI, but not to anti-Factor Xa activity...
  14. ncbi Low-molecular-weight heparins in thrombosis and cancer: emerging links
    Shaker A Mousa
    Pharmaceutical Research Institute at Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208, USA
    Cardiovasc Drug Rev 22:121-34. 2004
    ....
  15. ncbi Low-molecular-weight heparin in thrombosis and cancer
    Shaker A Mousa
    Albany College of Pharmacy and Pharmaceutical Research Institute PRI at Albany, Albany, New York 10001, USA
    Semin Thromb Hemost 30:25-30. 2004
    ..However, a direct anticancer effect for heparin in cancer patients without thrombosis still remains to be clinically documented...
  16. ncbi Antithrombotics in thrombosis and cancer
    Shaker A Mousa
    Albany College of Pharmacy, NY 12208 3492, USA
    Expert Rev Cardiovasc Ther 1:283-91. 2003
    ..Thus, modulation of tissue factor/VIIa noncoagulant activities by LMWH, warfarin, anti-VIIa or TFPI might be a useful therapeutic option for the inhibition of angiogenesis associated with human tumor growth and metastasis...
  17. ncbi Alpha v integrin affinity/specificity and antiangiogenesis effect of a novel tetraaza cyclic peptide derivative, SU015, in various species
    Shaker A Mousa
    Pharmaceutical Research Institute, Albany College of Pharmacy, Albany, New York 12208, USA
    J Cardiovasc Pharmacol 45:462-7. 2005
    ..These data also suggest that this bicyclic RGD analogue linked to a linker at the bottom leaves the RGD at the top available for binding and allows for conjugation with radioisotope for imaging and radiotherapy...
  18. ncbi Pharmacodynamic effects of low molecular weight heparin in obese subjects following subcutaneous administration of 75 IU/kg on plasma tissue factor pathway inhibitor and nitric oxide
    S A Mousa
    Albany College of Pharmacy and Pharmaceutical Research Institute, Albany, NY 12208, USA
    Int Angiol 24:40-2. 2005
    ..Pharmacodynamic effects of the low molecular weight heparin tinzaparin on plasma levels of tissue factor pathway inhibitor (TFPI) and nitric oxide (NO) were compared in obese subjects, as well as in normal healthy controls...
  19. ncbi Ximelagatran, the new oral anticoagulant: would warfarin survive the challenge?
    Shaker A Mousa
    Albany College of Pharmacy, The Pharmaceutical Research Institute, Albany, NY 12208, USA
    Cardiovasc Drug Rev 23:331-44. 2005
    ..The success of ximelagatran or other oral antithrombin agents would provide significant proof of the concept for the long-term use of oral antithrombins in the prevention and treatment of both arterial and venous thrombosis...
  20. ncbi Inhibitory effect of C-reactive protein on the release of tissue factor pathway inhibitor from human endothelial cells: reversal by low molecular weight heparin
    S A Mousa
    The Pharmaceutical Research Institute and Albany College of Pharmacy, Albany, NY 12208, USA
    Int Angiol 25:10-3. 2006
    ..The effects of C-reactive protein (CRP) and low molecular weight heparin (LMWH) on the release of tissue factor pathway inhibitor (TFPI) from human umbilical vein endothelial cells (HUVECs) were examined...
  21. ncbi Antithrombotics in thrombosis and cancer
    S A Mousa
    Albany College of Pharmacy, 106 New Scotland Avenue Albany, NY 12208 3492, USA
    Hamostaseologie 25:380-6. 2005
    ..Additionally, antiplatelet drugs could have an impact on tumour metastasis, and the combination of antiplatelets and anticoagulants at adjusted doses might provide greater benefits to cancer patients...
  22. pmc Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin
    Shaker A Mousa
    Pharmaceutical Research Institute at Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208, USA
    Thromb Haemost 96:816-21. 2006
    ..Both NA-LMWH and enoxaparin caused similar TFPI release from endothelial cells in vitro. These data provide evidence to support the potential of NA-LMWH as an anti-metastatic agent without any significant impact on coagulation...
  23. ncbi Pro-angiogenesis action of arsenic and its reversal by selenium-derived compounds
    Shaker A Mousa
    The Pharmaceutical Research Institute and Albany College of Pharmacy, 9 Samaritan Road, Albany, NY 12208, USA
    Carcinogenesis 28:962-7. 2007
    ..These data suggest that the pro-angiogenesis effect of arsenic is initiated at the plasma membrane integrin alphavbeta3, involves activation of the ERK1/2 pathway and is effectively reversed by various selenium-derived compounds...
  24. ncbi Elevation of plasma von Willebrand factor and tumor necrosis factor-a in obese subjects and their reduction by the low molecular weight heparin tinzaparin
    S A Mousa
    Albany College of Pharmacy, Albany, NY 12208, USA
    Int Angiol 24:278-81. 2005
    ..We compared associations between vWF level and markers of inflammation as well as the effects of LMWH in obese as compared to healthy human subjects...
  25. ncbi The proangiogenic action of thyroid hormone analogue GC-1 is initiated at an integrin
    Shaker A Mousa
    Pharmaceutical Research Institute at Albany and Albany College of Pharmacy, Albany, New York 12208, USA
    J Cardiovasc Pharmacol 46:356-60. 2005
    ..Thus, the proangiogenic effects of GC-1 and T4 are initiated at the plasma membrane, require interaction with alphavbeta3 integrin receptor, and are dependent on MAPK activation...
  26. pmc Synthetic oligosaccharide stimulates and stabilizes angiogenesis: structure-function relationships and potential mechanisms
    S A Mousa
    Pharmaceutical Research Institute at Albany and Albany College of Pharmacy, Albany, NY 12208, USA
    J Cardiovasc Pharmacol 48:6-13. 2006
    ..The proangiogenesis efficacy of an oligosaccharide is mediated via integrin alphavbeta3 and involves mitogen-activated protein kinase signaling mechanisms...
  27. ncbi Emerging links between thrombosis, inflammation and cancer: role of heparin
    S A Mousa
    The Pharmaceutical Research Institute and Albany College of Pharmacy, Albany, NY, USA
    Acta Chir Belg 105:237-48. 2005
  28. ncbi Angiogenesis inhibitors: current & future directions
    Shaker A Mousa
    Albany College of Pharmacy and Pharmaceutical Research Institute PRI at Albany, 106 New Scotland Avenue, Albany, NY 12208 3492, USA
    Curr Pharm Des 10:1-9. 2004
    ..Those strategies are driven from haemostatic, fibrinolytic, cell adhesion molecules, extracellular matrix, growth factors, and other endogenous systems involved in the modulation of angiogenesis...
  29. ncbi In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography
    Shaker A Mousa
    The Pharmaceutical Research Institute at Albany College of Pharmacy, Albany, New York 12208, USA
    Blood Coagul Fibrinolysis 18:55-60. 2007
    ..These data indicate differential enhanced thrombolysis of low levels of r-tPA with high-affinity Class I but not with low-affinity Class II GPIIb/IIIa antagonists in the absence of anticoagulants...
  30. ncbi The low molecular weight heparin, tinzaparin, in thrombosis and beyond
    Shaker A Mousa
    Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208 3492, USA
    Cardiovasc Drug Rev 20:199-216. 2002
    ..As compared with the standard heparin, LMWHs have different pharmacodynamic, and pharmacokinetic properties; they also differ in clinical benefits...
  31. ncbi Vitronectin receptors in vascular disorders
    Shaker A Mousa
    Albany College of Pharmacy, NY 12208 3492, USA
    Curr Opin Investig Drugs 3:1191-5. 2002
    ..This review will focus on the key role of the alpha v integrin (alpha v/beta3 and alpha v/beta5) in vascular disorders, such as angiogenesis-mediated disorders and vascular restenosis...
  32. ncbi Heparin and low molecular weight heparin in thrombosis and beyond
    Shaker A Mousa
    Albany College of Pharmacy, NY 12208 3492, USA
    Curr Opin Investig Drugs 3:1181-6. 2002
    ..Understanding the heparin structure led to the development of LMWHs, synthetic heparinomimetics, antithrombin and anti-Factor Xa agents...
  33. ncbi Differential efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet/fibrin-mediated clot dynamics under different conditions using thrombelastography: the critical need for anticoagulant
    Shaker A Mousa
    Albany College of Pharmacy, Albany, NY, USA
    Coron Artery Dis 13:243-8. 2002
    ..In contrast, oral delivery of GpIIb/IIIa antagonists failed in achieving clinical benefits. This raises the question about the differences among different GpII/IIIa antagonists...
  34. ncbi Antithrombotics and thrombolytics in stroke
    Shaker A Mousa
    Albany College of Pharmacy, NY 12208 3492, USA
    Curr Opin Investig Drugs 3:878-85. 2002
    ..The aim of this paper is to review the use of antithrombotics as prophylaxis treatment in stroke, in addition, to comparing the benefits/risks of using thrombolytics as acute intervention...
  35. ncbi Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications
    Shaker A Mousa
    Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208 3492, USA
    Curr Opin Chem Biol 6:534-41. 2002
    ..Integrin antagonists in clinical or pre-clinical development are expected to be used as a stand-alone therapy or, better, as an adjunct to other pharmacotherapy, radiotherapy or interventional procedures...
  36. ncbi alphav Vitronectin receptors in vascular-mediated disorders
    Shaker A Mousa
    Albany College of Pharmacy, Albany, New York 12208 3942, USA
    Med Res Rev 23:190-9. 2003
    ..This review will focus on the key role of the alphav integrin (alphavbeta3 and alphavbeta5) in vascular disorders such as restenosis and angiogenesis-mediated disorders...
  37. ncbi Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond
    Shaker A Mousa
    Albany College of Pharmacy, Albany, NY 12208 3492, USA
    Curr Pharm Des 9:2317-22. 2003
    ..This review highlights the role of the various antiplatelet therapies in thrombotic disorders as well as future directions...
  38. ncbi Recent advances of TNF-alpha antagonists in rheumatoid arthritis and chronic heart failure
    Shaker A Mousa
    Pharmaceutical Research Institute at Albany, Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208, USA
    Expert Opin Biol Ther 7:617-25. 2007
    ..Future investigation is needed to determine if individualized dosing of anti-TNF therapy is necessary and whether or not treating patients with earlier-stage disease will show a benefit...
  39. ncbi Heparin, low molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links
    Shaker A Mousa
    The Pharmaceutical Research Institute at Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208, USA
    Semin Thromb Hemost 33:524-33. 2007
    ..Heparin can effectively modulate all of those multifactorial components, as well as the interface among those components...
  40. ncbi From nutraceuticals to pharmaceuticals to nanopharmaceuticals: a case study in angiogenesis modulation during oxidative stress
    Shaker A Mousa
    Pharmaceutical Research Institute, Albany College of Pharmacy, Albany, NY, USA
    Mol Biotechnol 37:72-80. 2007
    ..Recent advances of the nanotechnology mediated gene delivery are also described in this paper...
  41. pmc Pharmacokinetics and pharmacodynamics of oral heparin solid dosage form in healthy human subjects
    Shaker A Mousa
    Pharmaceutical Research Institute at Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208, USA
    J Clin Pharmacol 47:1508-20. 2007
    ..Furthermore, the anti-factor Xa/anti-factor IIa ratio achieved is of approximately 1:1. This is the first true pharmacokinetic study to measure the chemical compositions of heparin administered by different routes...
  42. ncbi Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor
    Shaker A Mousa
    Albany College of Pharmacy, The Pharmaceutical Research Institute PRI, 106 New Scotland Avenue, Albany, NY 12208, USA
    Angiogenesis 11:183-90. 2008
    ....
  43. ncbi Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts
    M Yalcin
    The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, New York 12144, USA
    Anticancer Res 29:3825-31. 2009
    ..Overall, the findings presented here provide evidence for the anti-angiogenic, and anti-tumor actions of Tetrac and Tetrac NP and suggest their potential utility in the treatment of renal cell carcinoma...
  44. ncbi Tissue factor/VIIa in thrombosis and cancer
    Shaker A Mousa
    Albany College of Pharmacy, NY, USA
    Methods Mol Med 93:119-32. 2004
  45. doi Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid
    M Yalcin
    The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Albany, New York 12208, USA
    J Clin Endocrinol Metab 95:1972-80. 2010
    ..Tetrac also inhibits angiogenesis initiated by vascular endothelial growth factor and basic fibroblast growth factor...
  46. ncbi Effect of resveratrol on angiogenesis and platelet/fibrin-accelerated tumor growth in the chick chorioallantoic membrane model
    Sarah S Mousa
    Pharmaceutical Research Institute at Albany, NY 12208, USA
    Nutr Cancer 52:59-65. 2005
    ..These data suggest potential anticancer benefits as a chemopreventive and chemotherapeutic for the flavonoid resveratrol...
  47. ncbi Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface
    Faith B Davis
    Department of Veterans Affairs Medical Center, Albany, NY, USA
    Circ Res 94:1500-6. 2004
    ..Thus, thyroid hormone is shown to be a proangiogenic factor. This action, initiated at the plasma membrane, is MAPK dependent and mediated by FGF2...
  48. doi Adhesion molecules: potential therapeutic and diagnostic implications
    Shaker A Mousa
    Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA
    Methods Mol Biol 663:261-76. 2010
    ....
  49. doi Anti-cancer properties of low-molecular-weight heparin: preclinical evidence
    Shaker A Mousa
    The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, New York 12144, USA
    Thromb Haemost 102:258-67. 2009
    ..The benefits of LMWH in cancer might at least in part, be independent from its anti-coagulant activities, but may still be partially dependent on its anti-coagulant activities...
  50. ncbi Efficacy of anticoagulants and platelet inhibitors in cancer-induced thrombosis
    Melissa E Cloonan
    Pharmaceutical Research Institute at Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208, USA
    Blood Coagul Fibrinolysis 18:341-5. 2007
    ..The results between cancer-activated and tissue factor-activated blood were similar. The study concludes that an additive effect is present between LMWHs and a glycoprotein IIb/IIIa antagonist in reducing cancer-mediated thrombosis...
  51. ncbi Proangiogenesis action of the thyroid hormone analog 3,5-diiodothyropropionic acid (DITPA) is initiated at the cell surface and is integrin mediated
    Shaker A Mousa
    The Pharmaceutical Research Institute and Albany College of Pharmacy, New York 12208, USA
    Endocrinology 147:1602-7. 2006
    ..Thus, the proangiogenesis actions of thyroid hormone and its analog DITPA are initiated at the plasma membrane, apparently at integrin alphavbeta3, and are MAPK dependent...
  52. doi Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma
    Murat Yalcin
    Albany College of Pharmacy and Health Sciences, Pharmaceutical Research Institute, Rensselaer, New York 12144, USA
    Thyroid 20:281-6. 2010
    ..Here, the activity of tetrac and tetrac NP against follicular thyroid carcinoma (FTC)-236 cells was studied in two models: (1) tumor cell implants in the chick chorioallantoic membrane (CAM) system and (2) xenografts in the nude mouse...
  53. doi In vitro methods of evaluating antithrombotics and thrombolytics
    Shaker A Mousa
    Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA
    Methods Mol Biol 663:1-28. 2010
    ..A variety of methods have been used to assess platelet aggregation, blood coagulation, and the ex vivo and/or in vitro efficacy of platelet antagonists, anticoagulants, and thrombolytics...
  54. ncbi Tissue factor pathway inhibitor in thrombosis and beyond
    Shaker A Mousa
    Albany College of Pharmacy, NY, USA
    Methods Mol Med 93:133-55. 2004
  55. ncbi Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects
    Shaker A Mousa
    Albany College of Pharmacy and PRI, Albany, New York, USA
    J Clin Pharmacol 43:727-34. 2003
    ..Plasma levels of TFPI remained elevated compared with baseline values for 12 to 16 hours after drug administration. These results suggest that LMWH fractions < 2000 Da do not affect the release of TFPI...
  56. doi PPAR gamma ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis
    Ahmad Aljada
    Department of Biomedical Sciences, Long Island University, C W Post, Brookville, NY, USA
    Angiogenesis 11:361-7. 2008
    ....
  57. ncbi Cell adhesion molecules: potential therapeutic and diagnostic implications
    Shaker A Mousa
    Albany College of Pharmacy, NY, USA
    Methods Mol Med 93:157-74. 2004
  58. doi In vivo models for the evaluation of antithrombotics and thrombolytics
    Shaker A Mousa
    Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA
    Methods Mol Biol 663:29-107. 2010
    ..Finally, the use of genetic models of thrombosis/hemostasis and how these models have aided in the development of therapies that are presently being evaluated clinically are presented...
  59. ncbi Oral thrombin inhibitor ximelagatran
    Shaker A Mousa
    Albany College of Pharmacy, NY, USA
    Methods Mol Med 93:247-51. 2004
  60. ncbi Highlights of latest advances in antithrombotics
    Shaker A Mousa
    Albany College of Pharmacy, NY, USA
    Methods Mol Med 93:1-7. 2004
  61. ncbi OT-304, a novel, anti-angiogenesis agent with multiple inhibitory effects on proliferation, angiogenesis, and tumor progression
    S A Mousa
    Albany College of Pharmacy, Albany, NY Othera Pharmaceuticals, Exton, PA
    J Clin Oncol 26:14597. 2008
    ..Thus, a comprehensive anti-tumor strategy would be to target these processes. The present study tested a novel, oral, small molecule dual inhibitor of NF-κB and ERG-1 mediated, oxidative stress activation pathways...
  62. doi Semisynthesis and pharmacological activities of Tetrac analogs: angiogenesis modulators
    Alexandre Bridoux
    The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA
    Bioorg Med Chem Lett 19:3259-63. 2009
    ..Pharmacological activities showed Tetrac can accommodate numerous modifications and maintain anti-angiogenesis activity...
  63. doi Heparin and low-molecular weight heparins in thrombosis and beyond
    Shaker A Mousa
    Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA
    Methods Mol Biol 663:109-32. 2010
    ....
  64. ncbi Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells
    Faith B Davis
    Ordway Research Institute, Inc, Albany, NY 12208, USA
    Cancer Res 66:7270-5. 2006
    ..The present experiments infer a novel cell membrane receptor-mediated basis for the growth-promoting activity of thyroid hormone in such tumors and suggest new therapeutic approaches to the treatment of patients with glioblastoma...
  65. ncbi Heparin and low molecular weight heparin in thrombosis, cancer, and inflammatory diseases
    Shaker A Mousa
    Albany College of Pharmacy, NY, USA
    Methods Mol Med 93:35-48. 2004
  66. ncbi Cellular and molecular mechanisms of nicotine's pro-angiogenesis activity and its potential impact on cancer
    Sarah Mousa
    Pharmaceutical Research Institute, Albany College of Pharmacy, Albany, New York 12208, USA
    J Cell Biochem 97:1370-8. 2006
    ..01) the growth rate of breast, colon, and lung cancer. These data indicated that the pro-angiogenesis effect is mediated via b-FGF and induced through the nicotinic receptor, alphavbeta3 integrin, and MAPK...
  67. ncbi Are low molecular weight heparins the same?
    Shaker A Mousa
    Albany College of Pharmacy, NY, USA
    Methods Mol Med 93:49-59. 2004
  68. ncbi Anticoagulants in thrombosis and cancer: the missing link
    Shaker A Mousa
    Albany College of Pharmacy, Albany, New York, USA
    Semin Thromb Hemost 28:45-52. 2002
    ..Recent studies from our laboratory defined the role of an LMWH (tinzaparin), warfarin, anti-factor VIIa, and recombinant tissue factor pathway inhibitor in the modulation of angiogenesis, tumor growth, and tumor metastasis...
  69. ncbi Anticoagulants in thrombosis and cancer: the missing link
    Shaker A Mousa
    Albany College of Pharmacy, 106 New Scottland Ave, Albany, NY 12208 3492, USA
    Expert Rev Anticancer Ther 2:227-33. 2002
    ..Recent studies from our laboratory defined the role of the LMWH (tinzaparin), warfarin, antifactor VIIa and recombinant tissue factor pathway inhibitor in the modulation of angiogenesis, tumor growth and tumor metastasis...
  70. ncbi Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac)
    Anna B Glinskii
    Ordway Research Institute, Albany College of Pharmacy, Albany, NY, USA
    Cell Cycle 8:3562-70. 2009
    ..Nanoparticulate tetrac has coherent anti-cancer actions on expression of differentially-regulated genes important to survival of MDA-MB-231 cells...
  71. ncbi Arixtra (fondaparinux sodium)
    Shaker A Mousa
    Albany College of Pharmacy, NY, USA
    Methods Mol Med 93:239-46. 2004
  72. doi L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase
    Hung Yun Lin
    Ordway Research Institute, Albany, NY 12208, USA
    Am J Physiol Cell Physiol 296:C980-91. 2009
    ..T(3) action here is inhibited by tetrac alone, but the effect of T(4) is blocked by both tetrac and the RGD peptide...
  73. doi Novel anticoagulant therapy: principle and practice
    Shaker A Mousa
    Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA
    Methods Mol Biol 663:157-79. 2010
    ....
  74. doi Thyroid hormone and angiogenesis
    Mary K Luidens
    Signal Transduction Laboratory, Ordway Research Institute, Albany, NY 12208, USA
    Vascul Pharmacol 52:142-5. 2010
    ..The hormone also causes transcription of the matrix Gla protein (MGP) gene that opposes vascular smooth muscle calcification...
  75. ncbi Antiproliferative, antiangiogenesis, and reversal of chemoresistance by specific cathepsin L inhibitors
    A Rebbaa
    Albany College of Pharmacy and Health Sciences, Albany, NY
    J Clin Oncol 27:e14643. 2009
    ..et al., 2004 Cancer Res. 64:1773-80). In the present study, we sought to investigate the validity of these observations in vivo, and to dissect the underlying mechanism(s)...
  76. ncbi Nanoparticle-targeted delivery of nonanticoagulant heparin and doxorubicin in doxorubicin-resistant breast cancer
    D J Bharali
    The Pharmaceutical Research Institute, Rensselaer, NY
    J Clin Oncol 27:e11599. 2009
    ..Furthermore, custom-made nanoparticles with a targeted moiety on the surface would enable us to increase the efficacy and decrease the adverse effects of doxorubicin...
  77. doi Riociguat for the management of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
    N E Larche
    The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, New York, USA
    Drugs Today (Barc) 49:761-8. 2013
    ..Although long-term safety and efficacy and place in therapy remain to be established, riociguat presents as an exciting new option for the treatment of PH and potentially has additional indications in the near future. ..
  78. pmc Greasing the wheels of managing overweight and obesity with omega-3 fatty acids
    N Golub
    The University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Med Hypotheses 77:1114-20. 2011
    ..If these fatty acids do harbor such potential, their supplementation in many parts of the world may hold great promise in reducing the global burden of obesity...
  79. doi Pro- and anti-angiogenic agents
    A Bridoux
    Biomnis Laboratories R and D, 78, avenue de Verdun, 94200 Ivry sur Seine, France
    J Mal Vasc 37:132-9. 2012
    ....
  80. ncbi Obtustatin: a potent selective inhibitor of alpha1beta1 integrin in vitro and angiogenesis in vivo
    Cezary Marcinkiewicz
    Temple University, School of Medicine, Thrombosis Research Center, Philadelphia, Pennsylvania 19140, USA
    Cancer Res 63:2020-3. 2003
    ....
  81. ncbi Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats
    Rosemary J Santulli
    Johnson and Johnson Pharmaceutical Research and Development, Welsh and McKean Rds, Spring House, PA 19477 0776, USA
    J Pharmacol Exp Ther 324:894-901. 2008
    ..Given this profile, JNJ-26076713 represents a potential therapeutic candidate for the treatment of age-related macular degeneration, macular edema, and proliferative diabetic retinopathy...
  82. ncbi The role of tissue factor pathway inhibitor in tumor growth and metastasis
    Ali Amirkhosravi
    Institute of Translational Research, Florida Hospital, Orlando, Florida 32804, USA
    Semin Thromb Hemost 33:643-52. 2007
    ..The possible application of TFPI and other inhibitors of TF as potential anticancer agents is described, and information regarding potential antitumor properties of TFPI-2 (which has structural similarities to TFPI) is also included...
  83. ncbi Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis
    Shaker A Mousa
    DuPont Pharmaceuticals Company, 141 and Henry Clay Road, Exp Station, E400 3470, Wilmington, DE 19880 0400, USA
    J Cardiovasc Pharmacol 39:552-60. 2002
    ....
  84. ncbi Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454
    Ali Amirkhosravi
    Clinical and Research Laboratories, Florida Hospital Cancer Institute, 2501 N Orange Ave, Suite 786, Orlando, Florida 32804, USA
    Thromb Haemost 90:549-54. 2003
    ..001). Overall, these data provide further evidence for the effect of oral and intravenous GpIIb/IIIa antagonism on tumor cell-platelet interaction and metastasis...
  85. ncbi Anti-angiogenesis efficacy of the garlic ingredient alliin and antioxidants: role of nitric oxide and p53
    Ahmed S Mousa
    Cornell University, Ithaca, NY 14853, USA
    Nutr Cancer 53:104-10. 2005
    ..These data also suggest the implication of cellular NO and p53 as mediators of anti-angiogenesis and anticancer effects of alliin...
  86. ncbi Neutrophil-activating protein-2- and interleukin-8-mediated angiogenesis
    John A Powell
    University of Pennsylvania, Medical School, Philadelphia, Pennsylvania, USA
    J Cell Biochem 102:412-20. 2007
    ..These approaches may be a useful tool for the inhibition of angiogenesis associated with human tumor growth or with neovascular, ocular, and inflammatory diseases where chemokines and cytokines are involved...
  87. ncbi Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue
    Eric Dupont
    Les Laboratoires AEterna Inc, Quebec, Canada
    Clin Exp Metastasis 19:145-53. 2002
    ..In summary, our experimental data provide evidence of antiangiogenic and antimetastatic properties of Neovastat, following oral administration...
  88. ncbi Chronic pulsatile shear stress impacts synthesis of proteoglycans by endothelial cells: effect on platelet aggregation and coagulation
    Selim Elhadj
    Department of Chemical Engineering, Virginia Polytechnic Institute and State University, Blacksburg 24061, USA
    J Cell Biochem 86:239-50. 2002
    ..Our data suggests that shear stress, by altering proteoglycan synthesis and fine structure, may play a role in maintaining vascular hemodynamics and hemostasis...
  89. ncbi Signaling through JAM-1 and alphavbeta3 is required for the angiogenic action of bFGF: dissociation of the JAM-1 and alphavbeta3 complex
    Meghna U Naik
    Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA
    Blood 102:2108-14. 2003
    ..In addition, blockage of either JAM-1 or alphavbeta3 inhibits bFGF-induced MAP kinase activation. Thus, our results suggest that signaling through JAM-1 and alphavbeta3 is necessary for bFGF-induced angiogenesis...
  90. ncbi Antiplatelet, anticoagulant, and thrombolytic drug interactions
    Omer Iqbal
    Department of Pathology, Loyola University Medical Center, Maywood, IL, USA
    Methods Mol Med 93:9-20. 2004

Research Grants1

  1. Nanoparticle targeting of cathepsin-L inhibitor and doxorubicin in breast cancer
    Shaker Mousa; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..